Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Transl Res (2021) 227:7588
For some, having a weekly retatrutide injection that suppresses appetite and increases fat loss is an attractive idea
doi:10.1002/phar.70005
Weight loss averages 3-5% of body weight
We look forward to working with Ascendis to explore the potential of the TransCon technology platform to reduce the dosing frequency of GLP-1 receptor agonists and other treatments for cardiometabolic diseases. The TransCon tech is named after transient conjugation, which Ascendis describes as the companys unique ability to temporarily (transiently) link an inert carrier to a parent drug with known biology. The wide-ranging tech can help ensure drugs either act systemically throughout the body or locally
